Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory

Japanese Journal of Antibiotics

Volumn 60, Issue 6, 2007, Pages 394-403

  Sumitani, Yuko ^a   Kobayashi, Yoshio ^a  

^a KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIAPENEM; DORIPENEM; MEROPENEM;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG INFUSION; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; THEORETICAL STUDY;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; INFUSIONS, INTRAVENOUS; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 38549141552     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. 17th Europian Congress of Clinical Microbiology and Infectious Diseases/25th International Congress of Chemotherapy, abstructs, Munich, 2007
2. 46th International Conference on Antimicrobial Agents and Chemotherapy, abstracts, San Francisco, 2006
3. 16th Europian Congress of Clinical Microbiology and Infectious Diseases, abstructs, Nice, 2006
4. Japanese source
5. Japanese source
6. Japanese source
7. KUTI, J. L.; N. R. FLOREA, C. H. NIGHINGALE, et al.: Pharmacodynamics of meropenem and imipenem against enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy 24: 8-15, 2004
8. KUTI, J. L.; P. K. DANDEKER, C. H. NITINGALE, et al.: Use of Monte Carlo simulation to design an optimized pharmacodynamics dosing stratify for meropenem. J. Clin. Pharmacol. 43: 1116-1123, 2003
9. BHAVNANI, S. M.; J. P. HAMMEL, B. B. CIRINCIONE, et al.: Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategics for doripenem. Antimicrob. Agents Chemother. 49: 3944-3947, 2005
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fourteenth information supplement. NCCLS document. M100-S14. Wayne, PA: NCCLS, 2004
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth information supplement. CLSI document. M100-S14. Wayne, PA: CLSI, 2006
12. FREI, C. R. & D. S. BURGESS: Continuous infusion β-lactams for intensive care unit pulmonary infections. Clin. Microbiol. & Infect. 11: 418-421, 2005
13. BURGESS, D. S. & C. R. FREI: Comparison of β-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J. Antimicr. Chemother. 56: 893-898, 2005
14. Evidence-based medical guidelines. Orland regional medical center, 2007
15. KUTI, J. L.; C. H. NIGHTINGALE, R. QUINTILIANI, et al.: Pharmacodynamic profiling of continuously infused piparacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagnostic Microbiol. & Infect. Dis. 44: 51-57, 2002
16. KUTI, J. L.; C. H. NIGHTINGALE, R. F. KNAUFT, et al.: Pharmacokinetics properties and stability of continuous-infusion meropenem in adults with systic fibrosis. Clin. Ther. 26: 493-501, 2004
17. RODVOLD, K. A.: Pharmacodynamics of antiinfective therapy: Taking what we know to the patient's bedside. Pharmacotherapy 21: 319-330, 2001
18. ARINO, R. E.; A. NYHLEN, J. P. CONNELLY, et al.: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother. 39: 32-38, 2005